InvestmentUpdated on 27 August 2024
BRITE-A: Precision medicine for the treatment of obesity.
Innovation and Technology Transfer Manager at IBIMA Plataforma BIONAND
Málaga, Spain
About
A nanosystem consisting of a gold nanoparticle + surfactant + miRNA that acts as an anti-obesity drug and a nanosystem targeting system that allows its specific capture by adipose tissue (AT) in localized areas.
The miRNA acts on the white AT (energy storage) transforming it into beige AT (with thermogenic activity) while activating thermogenesis in both beige and brown AT (thermogenic activity).
Results
The nanosystem and the targeting system have been validated in an animal model of obesity, obtaining, among others, evidence of:
-
Decreased weight gain in animals fed a high-fat diet.
-
Overexpression of miRNA in tissue.
-
Overexpression of the thermogenesis pathway.
Stage
- Seed and Development
Applies to
- Biotech, Pharma and Cosmetics
Similar opportunities
Partnership
BRITE-A: Precision medicine for the treatment of obesity
- Others
María Mengual Mesa
Innovation and Technology Transfer Manager at IBIMA Plataforma BIONAND
Málaga, Spain
Product
- Distribution Partner
- Pharmaceutical industry
Ana Bouchet
CEO at LIFESOME THERAPEUTICS
MADRID, Madrid, Spain
Project cooperation
MODY-Tag: Diagnosis of diabetes MODY
- Research
- Execution
- Financing
María Mengual Mesa
Innovation and Technology Transfer Manager at IBIMA Plataforma BIONAND
Málaga, Spain